Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $170,400.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total transaction of $170,400.00. Following the completion of the transaction, the insider now owns 183,266 shares of the company’s stock, valued at $3,122,852.64. This represents a 5.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA traded up $0.36 during mid-day trading on Thursday, reaching $17.26. The company had a trading volume of 297,252 shares, compared to its average volume of 432,664. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 1-year low of $6.65 and a 1-year high of $18.97. The stock has a market cap of $2.27 billion, a PE ratio of -11.28 and a beta of 1.52. The company has a 50-day moving average price of $16.69 and a two-hundred day moving average price of $13.78.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently issued reports on CNTA. Guggenheim boosted their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. BMO Capital Markets boosted their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. B. Riley started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Finally, Jefferies Financial Group lifted their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $25.83.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. TD Asset Management Inc raised its holdings in shares of Centessa Pharmaceuticals by 40.5% in the second quarter. TD Asset Management Inc now owns 321,168 shares of the company’s stock valued at $2,900,000 after buying an additional 92,524 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Centessa Pharmaceuticals by 1.3% in the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company’s stock valued at $8,444,000 after acquiring an additional 12,031 shares during the last quarter. XTX Topco Ltd acquired a new stake in Centessa Pharmaceuticals in the second quarter worth $148,000. Farallon Capital Management LLC lifted its holdings in Centessa Pharmaceuticals by 438.0% during the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after acquiring an additional 1,625,000 shares in the last quarter. Finally, First Light Asset Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.